Cell line · CVCL_0237
Papers108
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 108
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Pharmacokinetic Tuning Redirects β‐Lapachone From NQO1 Bioactivation to Vimentin‐Targeted Oxidation in Cancer | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Basroparib inhibits YAP-driven cancers by stabilizing angiomotin. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combining antibody conjugates with cytotoxic and immune-stimulating payloads maximizes anti-cancer activity. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. | Drug Resist Updat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of Regulator of G Protein Signaling 11 Promotes Protumorigenic Features in Pancreatic Cancer. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SLC6A14-mediated glutamine promotes SYTL4-CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer. | Exp Mol Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenocarcinoma. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0237/papers